Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1003 | 1067 | 1055 | 1227 | 1445 | - |
Fund Return | 0.27% | 6.69% | 5.53% | 7.06% | 7.65% | - |
Place in category | 449 | 1166 | 472 | 27 | 55 | - |
% in Category | 36 | 88 | 39 | 3 | 8 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LifeStrategy 80 Equity Fund A Acc | 12.86B | 2.96 | 6.53 | 8.34 | ||
LifeStrategy 80 Equity Fund A Inc | 12.86B | 2.96 | 6.53 | 8.34 | ||
LifeStrategy 40 Equity Fund A Acc | 5.94B | 0.46 | 0.60 | 4.77 | ||
LifeStrategy 40 Equity Fund A Inc | 5.94B | 0.46 | 0.60 | 4.78 | ||
Vanguard Target Ret 2045 Acc Shares | 329.89M | -0.00 | 5.44 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LifeStrategy 80 Equity Fund A Acc | 12.86B | 2.96 | 6.53 | 8.34 | ||
LifeStrategy 80 Equity Fund A Inc | 12.86B | 2.96 | 6.53 | 8.34 | ||
Baillie Gifford Managed A Acc | 4.97B | 0.81 | -4.98 | 6.40 | ||
Baillie Gifford Managed A Inc | 4.97B | 0.82 | -4.98 | 6.40 | ||
Baillie Gifford Managed B Acc | 4.97B | 1.01 | -3.98 | 7.58 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
United States Treasury Bills | - | 2.18 | - | - | |
Microsoft | US5949181045 | 1.81 | 425.20 | +0.51% | |
AstraZeneca ADR | US0463531089 | 1.71 | 65.29 | +0.15% | |
Novartis | CH0012005267 | 1.66 | 91.95 | -0.44% | |
TotalEnergies SE | FR0000120271 | 1.63 | 55.84 | +0.22% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Neutral | Buy |
Technical Indicators | Strong Sell | Sell | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review